Literature DB >> 7477981

Levodopa-induced dyskinesias are improved by fluoxetine.

F Durif1, M Vidailhet, A M Bonnet, J Blin, Y Agid.   

Abstract

We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days. After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477981     DOI: 10.1212/wnl.45.10.1855

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism.

Authors:  M Naumann; M Götz; K Reiners; K W Lange; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 4.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

Review 5.  Treating and preventing levodopa-induced dyskinesias: current and future strategies.

Authors:  F Durif
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

6.  The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.

Authors:  Wei-Li Kuan; Jing-Wei Zhao; Roger A Barker
Journal:  Psychopharmacology (Berl)       Date:  2007-12-23       Impact factor: 4.530

Review 7.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

8.  Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata.

Authors:  Sarah Threlfell; Stephanie J Cragg; Imre Kalló; Gergely F Turi; Clive W Coen; Susan A Greenfield
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

10.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Authors:  Melissa M Conti; Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Rich Dell'isola; Aaron C Katzman; Christopher Bishop
Journal:  Neuropharmacology       Date:  2013-09-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.